Exelixis, Inc.: Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

- ADU-1805 is a potential best-in-class monoclonal antibody targeting SIRPa to block the SIRPa-CD47 checkpoint - - Phase 1 study of ADU-1805 as a single agent and in a combination regimen in advanced

Related Keywords

Laura Lassouw Polman ,Sairopabv Sairopa ,Gurvinder Singh Chahal ,Stekki Millman ,Dharminder Singh Chahal ,Susan Hubbard ,Vickil Goodman ,Drug Administration ,Nasdaq ,Exchange Commission ,Exelixis Inc ,Public Affairs ,Product Development Medical Affairs ,Chinook Therapeutics Inc ,Facebook ,Investigational New Drug ,Investigational New Drug Application ,Executive Vice President ,Chief Medical Officer ,Chief Operating Officer ,Van Herk Investments ,Chinook Therapeutics ,Aduro Biotech Europe ,Exelixi Annual Report ,Investors Contact ,Singh Chahal ,Media Contact ,Marcel Torney ,Exelixis ,Airopa ,Nnounce ,Clears ,Investigational ,Drug ,Application ,805 ,Patients ,Dvanced ,Olid ,Rumors ,